Dianthus Therapeutics Inc... (DNTH)
Dianthus Therapeutics Statistics
Share Statistics
Dianthus Therapeutics has 32.13M shares outstanding. The number of shares has increased by 9.46% in one year.
| Shares Outstanding | 32.13M |
| Shares Change (YoY) | 9.46% |
| Shares Change (QoQ) | 8.54% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 22.25M |
| Failed to Deliver (FTD) Shares | 142 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 5.92M, so 20.02% of the outstanding shares have been sold short.
| Short Interest | 5.92M |
| Short % of Shares Out | 20.02% |
| Short % of Float | 30.81% |
| Short Ratio (days to cover) | 22.54 |
Valuation Ratios
The PE ratio is -8.78 and the forward PE ratio is -6.46. Dianthus Therapeutics's PEG ratio is 0.12.
| PE Ratio | -8.78 |
| Forward PE | -6.46 |
| PS Ratio | 119.7 |
| Forward PS | 2.6 |
| PB Ratio | 2.12 |
| P/FCF Ratio | -9.53 |
| PEG Ratio | 0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Dianthus Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.22, with a Debt / Equity ratio of 0.
| Current Ratio | 15.22 |
| Quick Ratio | 15.22 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.02 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $79.94K |
| Profits Per Employee | $-1.09M |
| Employee Count | 78 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -28.48% in the last 52 weeks. The beta is 1.63, so Dianthus Therapeutics's price volatility has been higher than the market average.
| Beta | 1.63 |
| 52-Week Price Change | -28.48% |
| 50-Day Moving Average | 21.08 |
| 200-Day Moving Average | 24.95 |
| Relative Strength Index (RSI) | 38.17 |
| Average Volume (20 Days) | 313.35K |
Income Statement
In the last 12 months, Dianthus Therapeutics had revenue of 6.24M and earned -84.97M in profits. Earnings per share was -2.48.
| Revenue | 6.24M |
| Gross Profit | 6.24M |
| Operating Income | -101.86M |
| Net Income | -84.97M |
| EBITDA | -101.86M |
| EBIT | -101.86M |
| Earnings Per Share (EPS) | -2.48 |
Balance Sheet
The company has 22.79M in cash and 1.49M in debt, giving a net cash position of 21.3M.
| Cash & Cash Equivalents | 22.79M |
| Total Debt | 1.49M |
| Net Cash | 21.3M |
| Retained Earnings | -174.39M |
| Total Assets | 374.01M |
| Working Capital | 262.45M |
Cash Flow
In the last 12 months, operating cash flow was -78.18M and capital expenditures -105K, giving a free cash flow of -78.28M.
| Operating Cash Flow | -78.18M |
| Capital Expenditures | -105K |
| Free Cash Flow | -78.28M |
| FCF Per Share | -2.29 |
Margins
Gross margin is 100%, with operating and profit margins of -1633.74% and -1362.77%.
| Gross Margin | 100% |
| Operating Margin | -1633.74% |
| Pretax Margin | -1362.77% |
| Profit Margin | -1362.77% |
| EBITDA Margin | -1633.74% |
| EBIT Margin | -1633.74% |
| FCF Margin | -1255.57% |
Dividends & Yields
DNTH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for DNTH is $52, which is 218.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $52 |
| Price Target Difference | 218.6% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Sep 12, 2023. It was a backward split with a ratio of 1:16.
| Last Split Date | Sep 12, 2023 |
| Split Type | backward |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | 13.28 |
| Piotroski F-Score | 2 |